![](/img/cover-not-exists.png)
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HRâPositive , HER2âNegative Patients with Advanced Breast Cancer After FirstâLine Chemotherapy
Xu, Fei, Zheng, Qiufan, Xia, Wen, Ouyang, Quchang, Pang, Danmei, Yuan, Zhongyu, Shi, Yanxia, Peng, Roujun, Lu, Qianyi, Wang, ShusenJournal:
The Oncologist
DOI:
10.1002/onco.13614
Date:
November, 2020
File:
PDF, 512 KB
2020